The Nobel Assembly of Sweden's Karolinska Institute medical university selected American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel for the 2026 Nobel Prize in Physiology or Medicine. They will share 12 million Swedish crowns ($1.2 million) for discoveries concerning light-gated ion channels and optogenetics. One institution confers the prize, placing three researchers at the center of its scientific stage.
Optogenetics lets researchers switch individual nerve cells on or off in a living brain. Laboratories around the world use the method, while researchers investigate whether it could help restore vision or improve cochlea implants. Those possible applications matter to people living with disabilities, but the article describes research and clinical trials, not treatments already available to them. That's a distinction worth keeping in view.
Who Gets to Confer Recognition
Expert committees appointed by the prize-awarding institutions choose Nobel laureates. The medicine prize traditionally opens the annual Nobel announcements, followed over the coming days by awards in physics, chemistry, literature, peace and economics. The prize brings recognition and a substantial sum to its three recipients; appointed committees retain control of the selection process.
The work behind the award began with Peter Hegemann's investigation in the early 1990s into how the alga Chlamydomonas reacts to light in half a millisecond. He hypothesized that a single protein captured light and acted as an ion channel. Georg Nagel tested the idea by injecting Chlamydomonas genes into frog eggs, where he discovered channelrhodopsin-2, an ion channel that opens when exposed to light.
In 2003, Hegemann and Nagel published research showing that the protein could be introduced into human and hamster cells to generate electrical impulses using light. At Stanford, Deisseroth demonstrated the technique in rat nerve cells in 2005. Researchers named the method optogenetics. These steps came from named researchers and laboratories; the source describes no community-led research effort or grassroots response.
Potential Benefits, Still Under Study
In clinical trials, researchers are seeking to restore vision to people blinded by retinitis pigmentosa by inserting a light-sensitive protein into the retina. They also hope optogenetics could improve cochlea implants, allowing more precise stimulation of the auditory nerve than current electrical devices. A possible benefit under investigation isn't a delivered benefit, and the account doesn't claim either approach has become standard care.
Thomas Perlmann, Secretary-General of the Nobel Assembly at Karolinska Institutet, described the method as a way to switch individual nerve cells on or off. He said laboratories around the world use it to reveal the brain's mysteries. Perlmann also said he had spoken with all three laureates that morning. They were surprised and delighted, he said. Each called the others friends and described receiving the prize together as an honour.
The five original Nobel Prizes came from the will of Swedish inventor and industrialist Alfred Nobel and have been awarded since 1901, with limited interruptions, chiefly during World War One and World War Two. Sweden's central bank, the Riksbank, established a sixth award, the economics prize, in 1968. Past medicine laureates include Alexander Fleming, recognized for work on penicillin, and Karl Landsteiner, recognized for discovering human blood groups. Last year, American scientists Mary Brunkow and Fred Ramsdell and Japan's Shimon Sakaguchi won for work on how the immune system spares healthy cells.
The awards take place in Stockholm, except for the Peace Prize, which is handed out in Oslo. On Dec. 10, the laureates receive their awards at ceremonies attended by Sweden's and Norway's royal families and are honored at gala banquets. The science may reach far beyond those rooms; the prize-awarding institutions keep the authority to name its celebrated figures.